Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1/2a Open-label Clinical Trial of BI-1607, an Fc-Engineered Monoclonal Antibody to CD32b (FcγRIIB), in Combination with Trastuzumab in Subjects with HER2-positive Advanced Solid Tumors

Next Previous
Trial Profile

Phase 1/2a Open-label Clinical Trial of BI-1607, an Fc-Engineered Monoclonal Antibody to CD32b (FcγRIIB), in Combination with Trastuzumab in Subjects with HER2-positive Advanced Solid Tumors

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 18 Dec 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs BI 1607 (Primary) ; Ipilimumab (Primary) ; Pembrolizumab (Primary) ; Trastuzumab (Primary)
  • Indications Adenocarcinoma; Advanced breast cancer; Gastric cancer; Male breast cancer; Malignant melanoma; Oesophageal cancer; Solid tumours
  • Focus Adverse reactions; First in man; Proof of concept
  • Acronyms CONTRAST

Most Recent Events

  • 16 Dec 2024 Status changed from active, no longer recruiting to discontinued after the completion of phase IA, for business reasons.
  • 12 Dec 2024 According to a BioInvent International media release, preliminary data from the study expected next year.
  • 12 Dec 2024 According to a BioInvent International media release, approximately 35 patients will be enrolled in 10 to 12 sites located in the UK, Germany and Spain with first data expected in H2 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top